- Fraudulent Email Warning（27KB）
News Release
- November 20, 2025
- Announcement of Spryte Medical, a US Affiliate of NIPRO, Receives FDA IDE Approval to Initiate "INSYTE" US Pivotal Trial evaluating the nOCT Imaging System during Brain Aneurysm Treatment (135KB)
- November 4, 2025
- Notice of Personnel Changes (165KB)
- October 28, 2025
- Notice Concerning Acquisition of Shares of G2/Spryte Holdco, LLC (to Make It a Subsidiary) (130KB)
IR News
- November 21, 2025
- Toward NIPRO's Sustainable Growth
- November 10, 2025
- Consolidated Financial Results for the Six Months Ended September 30, 2025 [Japanese GAAP] / Notice Regarding Difference between Consolidated Financial Forecasts and Actual Results for the Six Months Ended September 30, 2025 / IR Materials
- September 30, 2025
- Annual Report
Our Business
Meeting the needs of front line medical treatment with unique products and technologies
To meet the needs of the front line of medical treatment, NIPRO creates unique products at its four research and development sites while leveraging the technologies cultivated in its various businesses.
Mission, Vision, Value
We will work as a truly global comprehensive medical manufacturer with a willingness to consider patient and user viewpoints.
